ReWalk exoskeleton sales jumped 13% to $2.5 million, and AlterG services climbed 25% to $4.1 million, underpinning the Revenue boost.

Lifeward posted Q2 2026 revenue of $6.6 million, a 16% increase from the prior year, while cash rose to roughly $11 million after a $5.6 million Capital infusion. The stronger Top Line and expanded Liquidity give investors confidence in the company’s execution and funding runway.

Key Highlights

  • Revenue rose 16% to $6.6 million, driven by a 13% lift in ReWalk exoskeleton sales to $2.5 million and a 25% rise in AlterG services to $4.1 million.
  • Cash balance increased to $9.4 million at quarter‑end and to a pro‑forma $11 million after a $5.6 million raise, with up to $5.6 million more tied to sales milestones or a $13.80 share price.
  • Operating loss narrowed 37% to $4.2 million and net loss widened to $11.5 million, while gross Margin slipped to 41% from 44% a year earlier.

Lifeward Ltd. (NASDAQ: LFWD) announced second‑quarter 2026 revenue of $6.6 million, a 16% rise from the comparable period a year earlier, and a cash balance that now sits at $9.4 million, projecting to $11 million after a recent financing. The company also disclosed the resignation of three directors on August 13 and the planned departure of Chief Financial Officer Almog Adar effective September 30, 2026. These operational and governance shifts accompany a $5.6 million infusion from a July 6 financing that can expand to $11.2 million.

The revenue uplift and cash strengthening together broaden Lifeward’s capacity to fund its growth initiatives.

Revenue and Governance Changes

The quarter’s top‑line expansion reflects a 13% increase in ReWalk Personal exoskeleton sales, generating $2.5 million, and a 25% rise in AlterG services, contributing $4.1 million. MyoCycle FES bike sales remained flat at $0.1 million. Gross margin fell to 41%, down from 44% a year earlier, as higher tariffs, foreign‑exchange fluctuations, and a 4% revenue‑sharing expense linked to the Oramed transaction weighed on profitability.

The combined effect of revenue gains and Leadership turnover positions the firm to pursue its capital‑efficient distribution model, yet the reduced margin highlights cost pressures that must be managed.

Financing Mechanics and Cost Structure

Despite lower expenses, operating loss improved by 37% to $4.2 million, while net loss widened to $11.5 million, driven by non‑cash fair‑value charges on warrants and derivatives. The financing structure and expense reduction together improve cash flow, yet the lingering net loss underscores the need for continued revenue momentum.

Execution Momentum and Market Position

The surge in ReWalk and AlterG sales underscores the effectiveness of Lifeward’s capital‑efficient distribution strategy, which leverages established rehabilitation and durable‑medical‑equipment partners. In August, the firm launched a pilot with Ottobock Care, extending ReWalk Personal Exoskeleton access across more than 50 U.S. clinics. This partnership, combined with a strong sales pipeline, supports management’s view that revenue momentum will continue into the second half of 2026.

Meanwhile, the ORMD‑0801 oral insulin program advances toward a Phase 2 U.S. trial, funded through the Oratech acquisition. The blend of product diversification, expanded distribution, and ongoing clinical development fuels confidence that the company can sustain growth, even as gross margins face headwinds.

Forward Catalyst and Governance Outlook

The conditional $5.6 million Tranche tied to either a 150% sales uplift or a $13.80 share price provides a clear milestone that could further augment liquidity. As the company progresses toward its next quarterly report, performance against these triggers will indicate whether the financing benefits materialize and whether the recent governance changes translate into operational stability.

Peers Moving on This News